Latanoprost first choice for European & US doctors

Article

American and European physicians prefer to treat glaucoma with prostaglandin monotherapy, most commonly latanoprost.

American and European physicians prefer to treat glaucoma with prostaglandin monotherapy, most commonly latanoprost, according to the results of a survey published in the March/April issue of the European Journal of Ophthalmology.

William Stewart from the University of South Carolina and colleagues from the PRN Pharmaceutical Research Network and the Charleston Research Company, USA distributed 1,000 multiple-choice surveys by e-mail to US and European physicians.

A total of 71 physicians responded (US 40 and EU 31). Most of the respondents preferred prostoglandin monotherapy (US 39 [98%] and EU 22 [71%]), usually latanoprost (US 32 [80%] and EU 22 [71%]). When more efficacy was required, US doctors were more likely to switch treatments, whereas European doctors preferred to add additional therapy.

These results demonstrate that both EU and US doctors prefer to treat glaucoma with prostaglandin monotherapy.

Related Videos
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Disrupting the glaucoma treatment paradigm with novel femtosecond laser from ViaLase
2-year data in contralateral eye evaluation gives edge to iStent inject over Hydrus stent
Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in
Investigating the effects of canaloplasty on corneal epithelium
© 2024 MJH Life Sciences

All rights reserved.